

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2023

Vol. 51, No. 6

CONTENTS

SPECIAL SECTION ON PERSPECTIVE ON DRUG METABOLISM

AND DISPOSITION, PART I

50TH ANNIVERSARY CELEBRATION COLLECTION

Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial. Yurong Lai and Xinxin Ding **645**

[S] Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance. *Matthew A. Cerny, Douglas K. Spracklin, and R. Scott Obach* **647**

Fifty Years of Aryl Hydrocarbon Receptor Research as Reflected in the Pages of *Drug Metabolism and Disposition*. *David S. Riddick* **657**

Epigenetic Mechanisms Contribute to Intraindividual Variations of Drug Metabolism Mediated by Cytochrome P450 Enzymes. *Jing Jin and Xiao-bo Zhong* **672**

Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research. *Joseph M. Cronin and Ai-Ming Yu* **685**

[S] Impact of Intracellular Lipid Binding Proteins on Endogenous and Xenobiotic Ligand Metabolism and Disposition. *King Clyde B. Yabut and Nina Isoherranen* **700**

MINIREVIEW

50TH ANNIVERSARY CELEBRATION COLLECTION

[S] Combined Oral Contraceptives As Victims of Drug Interactions. *Li Li, Xinning Yang, Doanh Tran, Shirley K. Seo, and Yanhui Lu* **718**

ARTICLES

[S] Characterization of Enzymes Involved in Nintedanib Metabolism in Humans. *Shimon Nakashima, Rei Sato, Tatsuki Fukami, Takashi Kudo, Shiori Hashiba, Gaku Morinaga, Masataka Nakano, Eva Ludwig-Schwellinger, Akiko Matsui, Naoki Ishiguro, Thomas Ebner, and Miki Nakajima* **733**

[S] A Physiologically-Based Pharmacokinetic Model for Cannabidiol in Healthy Adults, Hepatically-Impaired Adults, and Children. *Sumit Bansal, Mayur K. Ladumor, Mary F. Paine, and Jashvant D. Unadkat* **743**

[S] Complex Metabolism of the Novel Neurosteroid, Ganaxolone, in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment. *William L. Fitch, Steven Smith, Michael Saporito, Gregory Busse, Mingbao Zhang, Julie Ren, Michael E. Fitzsimmons, Ping Yi, Stephen English, Adam Carter, and Thomas A. Baillie* **753**

[S] Inactivation of Human Aldehyde Oxidase by Small Sulfhydryl-Containing Reducing Agents. *Mariam Esmaeeli, Manfred Nimtz, Lothar Jänsch, Lloyd W. Ruddock, and Silke Leimkühler* **764**

[S] Mechanistic Study of Icaritin-Induced Inactivation of Cytochrome P450 2C9. *Xiang Chen, Luyao Han, Yulin Zhao, Haoyan Huang, He Pan, Chenmeng Zhang, Huili Chen, Shanliang Sun, Sihui Yao, Xijing Chen, and Yongjie Zhang* **771**

[S] Mechanistic Investigation of the Time-Dependent Aldehyde Oxidase Inhibitor Hydralazine. *J. Paige Barnes, Shaoyun M. Yang, Taylor S. Thompson, Caithlyne M. Guevarra, Shaniya S. Pleasant, Tri Q. Do, and Rachel D. Crouch* **782**

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: “Binding characteristics of xenobiotic ligands of FABPs.” See the article by Yabut and Isoherranen ([dx.doi.org/10.1124/dmd.122.001010](https://doi.org/10.1124/dmd.122.001010)).